Skip to main content

Table 2 Cox proportional hazard analyzes for PFS after CBZ treatment

From: The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients

 

Univariate

Multivariate

 

Odds ratio (95% CI)

P

Odds ratio (95% CI)

P

Age (y) > 70

0.90 (0.60–1.35)

0.617

  

PS ≥ 1

1.04 (0.69–1.56)

0.864

  

GS ≥ 9

1.00 (0.65–1.53)

0.982

  

PSA (ng/ml) > 100

0.93 (0.62–1.41)

0.743

  

Hb (g/dl) < 12

1.245 (0.828–1.871)

0.292

  

LDH (U/L) > 300

1.28 (0.81–2.02)

0.298

  

ALP (U/L) > 350

0.93 (0.62–1.40)

0.739

  

Bone meta at diagnosis

1.55 (1.03–2.34)

0.037*

1.03 (1.03–2.37)

0.037*

Time to CRPC (y) < 1

1.19 (0.79–1.79)

0.4

  

DTX cycle< 10

1.40 (0.92–2.13)

0.121

  

ABI or ENZA

0.73 (0.45–1.17)

0.184

  

Low initial CBZ dose

1.03 (0.67–1.58)

0.905

0.95 (0.62–1.47)

0.832

RDI 60% or lower

0.86 (0.54–1.39)

0.545

  
  1. PS performance status, DTX docetaxel, ABI abiraterone, ENZ enzalutamide
  2. RDI relative dose intensity, *P < 0.05
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us